
4th Annual Process Development for Cell Therapies Summit
Driving Process Robustness, Scalability, Speed & Affordability
Newsletters and Deep Dive digital magazine
Driving Process Robustness, Scalability, Speed & Affordability
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
HHS Secretary Robert F Kennedy Jr would not explicitly endorse measles vaccines at Congressional hearings, and deflected questions on department cuts.
Editor's Picks
Newsletters and Deep Dive
digital magazine